CPA Management Accompany AstraZeneca Delegation to SIPO Meeting
On 17 August 2017, a delegation of AstraZeneca PLC visited the State Intellectual Property Office of China (SIPO) accompanied by China Patent Agent (H.K.) Ltd. (CPA)'s Deputy General Manager Ms. Tina Tai and Chemistry Department Deputy Manager Mr. Guo Yu.
During the meeting, the delegation exchanged views with SIPO's Vice Commissioner Mr. Gan Shaoning, Legal Affairs Department Director-General Ms. Song Jianhua, and Pharmaceutical and Biological Invention Examination Department Director-General Ms. Feng Xiaobing on topical issues including IP protection in China, the fourth revision of the Chinese Patent Law, and pharmaceutical patent linkage system. According to Mr. Pascal, AstraZeneca as a research-based, innovation-oriented biopharmaceutical company has always attached importance to the protection of IP, and cherished the opportunity of enhancing communication and strengthening cooperation with SIPO. Mr. Gan also recognised that such exchanges enabled SIPO to hear the voice of AstraZeneca as a stakeholder, and hence were useful and constructive to the betterment of the Chinese IP protection system.
The AstraZeneca delegation comprised its Executive Director and Chief Executive Officer Mr. Pascal Soriot, Executive Vice-President (International) Mr. Leon Wang, General Manager (China) Ms. Feng Ji, and General Counsel (China) Ms. Wang Weiying.
